Scarlet Therapeutics

Bristol-based biotechnology company Scarlet Therapeutics has successfully secured £3.2 million in seed funding to advance its universal blood cell therapy.Summary of transaction details:Value: £3.2 millionSector: Healthcare & BiotechAdvisor: Not mentionedKey Entities: Target: Scarlet TherapeuticsLocation: Bristol, UKNote: This funding round will enable Scarlet Therapeutics to further develop its proprietary lab-grown red blood cells, which are designed to be universally compatible, removing the need for blood-type matching in transfusions and addressing a broad patient demographic.

Investor: Meltwind, Science Creates Ventures